Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Receivables (2024 - 2025)

Historic Receivables for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Q3 2025 value amounting to $16.7 million.

  • Day One Biopharmaceuticals' Receivables rose 9202.99% to $16.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.7 million, marking a year-over-year increase of 9202.99%. This contributed to the annual value of $13.9 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' Receivables is $16.7 million, which was up 9202.99% from $19.7 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Receivables' 5-year high stood at $19.7 million during Q2 2025, with a 5-year trough of $8.7 million in Q3 2024.